Oral Cancer Therapy: Policy Implications for the Uninsured and Underinsured Populations
Beth Faiman, CNP
From Cleveland Clinic, Cleveland, Ohio
Ms. Faiman has acted as a consultant for Celgene, Millennium, and Onyx Pharmaceuticals.
Correspondence to: Beth Faiman, CNP, Cleveland Clinic Foundation, 9500 Euclid Avenue R35, Cleveland, OH 44195. E-mail: email@example.com
J Adv Pract Oncol 2013;4:354–360 |
DOI: 10.6004/jadpro.2013.4.5.7 |
© 2013 Harborside Press®
Approximately 25% of the nearly 400 anticancer drugs that are currently in development will be available in oral formulations. Yet in many states, while IV medications are reimbursed without substantial out-of-pocket costs to the patient, oral medications can be associated with excessive copays or not reimbursed at all.
For access to the full length article, please sign in